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Aim. The aim was to study the influence of booster immunization with recombinant fragment of E2 CSFV on
humoral immune response, elicited by candidate marker DNA-vaccine against CSF. Methods. The fragment of
E2 CSFV gene has been detected by PCR, and the expres- sion of encoded protein – by immunohistochemical
analysis. The anti-E2 antibodies in blood serum after immunization have been detected by ELISA. Results. It has
been shown that candidate marker DNA-vaccine transfected myocytes of murine biceps in situ. The data of
immuno-histochemical analysis revealed the expression of fragment of glycoprotein E2 CSFV from the plasmid
introduced. The booster immunization with recombinant E2 led to the significant increase of the titer of
antibodies specific to the antigen studied. Conclusions. The data obtained show that boosting with recombinant
E2 enhances humoral immune response elicited by the candidate marker DNA-vaccine against CSF.
Keywords: marker DNA-vaccine, booster immunization, humoral immune response, classical swine fever virus.
Introduction. Classical swine fever (CSF) is a
dangerous highly contagious disease. It is included
into the list A of the Office International des
Epizooties (OIE). Periodic outbreaks of this disease,
observed everywhere except for USA, Canada,
Australia, New Zealand, Iceland, Ireland, Norway and
Sweden, are of considerable damage to animal hus-
bandry. The causative agent of this disease is a
member of Flaviviridae family – the virus of classical
swine fever (CSFV). The attenuated vaccines against
CSF, present in the market, do not provide for
serological discrimination between post-infectious
and vaccine-induced immunity. This aspect is
especially significant in detecting chronically infected
animals which do not develop any clinical signs of the
disease for a long time, and thus, may be a source of
spreading virulent CSFV in the livestock. Taking this
fact into consideration, many countries, including EU
member states, practice complete elimination of infec-
ted and potentially infected animals and ban the vac-
cination against CSF.
Recently the first marked subunit vaccine against
CSF, based on the application of the main protective
antigen E2 of CSFV glycoprotein [1], has appeared on
the market. However, the literature data testify that it is
less efficient than, for instance, attenuated vaccine of
strain C. Since the intensity of humoral immune
response is a key factor, determining the possibility of
infecting animals with CSFV and the development of
long-term symptom-free virus carriage [2], the search
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for efficient marked vaccine against this disease is an
urgent trend of veterinary virology.
In the prevailing numbers of works, dedicated to the
creation of marked DNA-vaccine against CSF, a complete
sequence of glycoprotein E2 CSFV was used [3–5]. At the
same time it is suggested to differentiate between
vaccine-induced and post-infectious immunity of animals
by test-systems determination of antibodies to Erns. It
should be noted that the creation of DNA-vaccine in the
works [6, 7] involved the application of E2 gene
fragments, not containing the sequence, encoding the
signaling peptide and transmembrane domain, while all
antigenic subdomains were preserved similarly to a wild
type protein.
In our previous work we reported about the creation of
candidate marked DNA-vaccine against CSF on the basis
of the gene fragment, coding for antigenic subdomains A
and D of glycoprotein E2 CSFV [8].
The approach, proposed by us, is advantageous by the
application of different antigenic subdomains of E2 for the
elaboration of both marked DNA-vaccine and recom-
binant protein-based diagnosticum which will allow in-
creasing the accuracy of differentiation between vaccine-
induced and post-infectious immunity in animals due to
the simultaneous detection of antibodies against two
protective antigens of E2 (subdomains B and C) and Erns .
The recent literature data have shown that the booster
immunization with recombinant protein [9] or
recombinant virus, for instance, adenovirus [10, 11], after
the priming with DNA-vaccine may result in considerable
increase in the immune response to DNA-vaccination.
Therefore, this work was aimed at the investigation of
an impact of the booster immunization with recombinant
fragment of E2 CSFV on the humoral immune response,
induced by candidate marked DNA-vaccine against CSF.
Materials and Methods. The strains of Escherichia
coli Sure®2 (Stratagene, USA) and BL 21 (DE3) (Novag-
en, Germany) were used in the work. The preparations of
plasmid DNA were isolated and purified by alkaline lysis
with subsequent phenol/chloroform extraction in
accordance with the methods, described in [12–14].
Immunization. The experiments were conducted on
female mice of BALB/c line (breeding of IMBG, NAS of
Ukraine), 2–2.5 months old. All the manipulations with
animals were conducted using sedative and anesthetic
preparations in compliance with the requirements of
veterinary legislation. To study the expression of E2
CSFV fragment in situ the animals (n = 6) were
injected intramuscularly with 100 µg of
pTR-BKneo
-, dissolved in 100 µl of the saline, into
the biceps. The control animals were injected with
100 µg of the initial vector pTR-UFneo-. The
expression of the fragment studied was monitored
on the third day after the injection. The scheme of
combined immunization is described in Results and
Discussion. The number of animals in each group
was seven. The blood for isolation of serum was
obtained by retro-orbital puncture on the 21, 42 and
65th days after the beginning of the immunization;
blood serum was obtained as described in [8].
The immunohistochemical determination of the
expression of E2 CSFV fragment in situ. On the 3rd
day after the injection of the plasmid DNA
preparation the mice were euthanized. The biceps
was isolated, placed on the objective table of the
cryostat device at the temperature of – 25 C and
serial 20 µm-thick cuts were made with subsequent
fixation with 0.25 % aqueous solution of glutaric
dealdehyde for 5 min. The immunohistochemical
determination of the E2 fragment expression was
conducted by the following method: primary
antibodies were applied to the sections (hyper-
immune swine serum obtained according to [8] in
the working dilution of 1:1000 in phosphate-saline
buffer, pH 7.4, containing 0.05 % twin-20 (PSBT)
and 1 % skim milk. Then the sections were incuba-
ted at the temperature of 37 C for 2 h and washed
with PSBT three times with subsequent introduction
of antibodies against swine immunoglobulins (Sig-
ma, USA), conjugated with horseradish peroxidase
in the working dilution of 1:500. [Next,] They were
incubated for 2 h and washed with PSBT five times.
3-aminoethylcarbasol (Sigma) was used as
chromogen. The sections were additionally stained
with 1 % aqueous solution of azur-II.
The total DNA from the biceps tissue was
extracted by the mixture of phenol-chloroform
according to the method described in [15].
The detection of E2 CSFV fragment by PCR. A
pair of primers was selected to detect the transgene
using PCR: Å2asn – 5'-GGCACCAAAATCAACG
GGAC-3' and E2sn – 5'-GGGAGTCCGTC
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AGCCTCAT-3'. The reaction mixture contained 100
ng of total DNA. The amplification of the fragment of
glycoprotein E2 CSFV was conducted on DNA-
amplifier Tercik (DNA-technologies, RF) using the fol-
lowing scheme: DNA denaturation – 95 C, 30 s ; ann-
ealing primers – 60 C, 30 s ; elongation – 72 C, 1 min.
After the process the amplification products were
separated using the gel-electrophoresis method in 0.8 %
agarose gel.
The expression of the fragment E2 CSFV in E. coli
BL21 (DE3) and its purification. The bacterial culture
was cultivated in nutrient media: LB [12],
BactoTMBrain heart infusion Porcine (BD Biosciences,
USA) (hereinafter medium II) and Bacto NZCYM
Broth (Difco, USA) (hereinafter medium NZCYM),
containing kanamycin and glucose in the final
concentration of 50 µg/ml and 0.5 % respectively. The
inoculate of E. coli cells BL(DE3)/pET24ap -csfcrev,
previously cultivated at 37 C for 16–18 h, was
introduced into the nutrient medium. The volume ratio
of inoculate and nutrient medium was 1:100. The cul-
ture was cultivated upon intense aeration (160 rpm) at
37 C until reaching the optic density of A600 = 2; to
induce the target product synthesis we added the
solution of isopropyl--D-thiogalactoside (IPTG, MBI
Fermentas, Lithuania) to the final concentration of 1
mM and continued the cultivation of producent strain
under the same conditions during 4–16 h. The
inclusion bodies, containing E2 fragment, were
isolated in accordance with [16] and solubilized in the
buffer solution, containing 8 M urea and 0.1 M DTT.
The solubilized protein was transferred into the buffer
solution without urea and DTT using gel-filtration on
Sephadex G-25 (GE Healthcare, USA). The
chromatographic purification of preparations was
performed on Q Sepharose XL (GE Healthcare). The
fractions obtained were analyzed by gel-electropho-
resis using Laemmli's method in 13 % SDS-PAAG
[12]. The content of the target protein in the lysate of E.
coli cells was estimated using the densitometry of
electrophoregrams with subsequent analysis in Total
Lab software (USA).
The antibodies, specific to E2 CSFV in murine
blood serum, were detected by ELISA according to [8].
The results are presented as the average value of optic
density index at the used dilution ± average deviation
(n = 7). In order to assess the relevance of discrepancies
we used the non-parametric Mann-Whitney criterion
(U). The index of seroconversion was calculated as the
percentage ratio of the number of animal sera with
titers of anti-E2 antibodies > 1/50, obtained after the
vaccination to the total number of the sera studied. The
results are presented as the average value of the index
(obtained in three groups, seven animals in each).
Results and Discussion. In our previous work we
showed in vitro that the introduction of developed
recombinant plasmid pTR-BKneo- in the cells of
CHO-K1 line leads to the expression of E2 CSFV
fragment [8]. One of the key stages in the elaboration
of DNA-vaccines as well as other gene-based
therapeutic preparations is the confirmation of the
transfer of genetic material, namely, a target gene or
genes into the target cells of the recipient organism and
confirmation of the functional activity of the
developed recombinant molecules in situ. The
presence of transgene in the zone of the administration
and expression of the target protein was studied on the
3rd day after the intramuscular injection of
pTR-BKneo-. A pair of primers was designed to test the
transgene using PCR: Å2asn – 5'-
GGCACCAAAATCAACGGGAC-3' and E2sn -
5'-GG GAGTCCGTCAGCCTCAT-3' (Fig.1). The
length of the expected PCR-fragment is 701 b.p. The
PCR-analysis of the samples of total DNA, isolated
from the biceps tissue, demonstrated the presence of the
transgene of the fragment of E2 CSFV in the biceps
cells of experimental animals, which is evidenced by
the band of expected size on the electrophoregram of
PCR-reaction products (Fig.2). At the same time this
fragment is absent in the control samples. Therefore,
the obtained data revealed that the developed construct
pTR-BKneo-, administered by the chosen route ,
transforms in situ the biceps cells.
The target antigen expression was studied by
immunohistochemical method on the 3rd day after the
introduction of the candidate marker DNA-vaccine.
The results obtained testify to the fact that the target
antigen is expressed by the biceps myocytes on the 3rd
day after the intramuscular introduction of the
investigated DNA-vaccine (Fig.3). However, the
percentage of transfected cells turned out to be small –
2.42 ± 0.17 %, which is in good agreement with the
literature data [17]. It should be also noted that although
in the prevailing majority of cases the fragment of E2
glycoprotein was expressed by the cells of
cross-striped muscles, there were single variants of its
expression by the cells of the vessel wall of the venule,
which most likely are the cells of smooth muscles or
endotheliocytes. The expression of the target antigen
by these cells may provide its direct occurrence in the
blood flow, and therefore possible enhancement of the
immune response due to the contact with a large
number of antigen-presenting cells in the draining
lymph nodes, spleen etc.
The action of booster immunization was studied
using recombinant fragment E2 CSFV, obtained in E.
coli cells. Although the recombinant protein is not
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PcmvTR
TRE2 pA2
701 b p
E2asn E2sn Fig. 1 The scheme of the location of primers
in the fragment of glycoprotein gene E2
CSFV relative to its structural map in the
composition of plasmid pTR-BKneo
-
; TR –
inverted terminal repeats AAV-2; Pcmv –
human cytomegalovirus immediate-early en-
hancer/promoter; E2 – SacI-EcoRI-fragment
of E2 CSFV gene; pA2 – signal of poly-
adenylation
1 2 3 4 5 6 7 8
 701 b p
Fig. 2 The electophoregram of PCR products, obtained using primers
E2-sn/E2-asn: 1 – sample without DNA (control); 2 – total DNA
extracted from biceps cells on the 3
rd
day after the introduction of
plasmid DNA; 3 – pTR-BKneo
-
; 4–6, 8 – total DNA extracted from
biceps cells on the 3
rd
day after the introduction of pTR-BKneo
-
; 7 –
marker (FastRuler
TM
DNA Ladder, Low Range, Fermentas). The size of
PCR products is indicated with an arrow.
A B
Ðèñ. 3. Èììóíîãèñòîõèìè÷åñêîå
îïðåäåëåíèå ýêñïðåññèè ôðàã-
ìåíòà ãëèêîïðîòåèíà Å2 ÂÊ×Ñ â
êëåòêàõ áèöåïñà ìû- øè íà 3-è
ñóò ïîñëå ââåäåíèÿ: à – êîíòðîëü-
íàÿ ãðóïïà; á – ýêñïåðèìåíòàëü-
íàÿ ãðóïïà, êî- òîðîé ââîäèëè
pTR-BKneo
–
.  400
glycosilated in E. coli cells, it was previously de-
monstrated that the immunization of swine with this
fragment elicited a protective immune response, suf-
ficient to protect the animals against the challenge with
CSFV, strain Washington [16].
To enhance the yield of the target antigen we
optimized the conditions of cultivating the producent
strain BL21 (DE3)/pET24ap-csfc@rev, developed
previously [16]. It was shown that the cultivation on
complex nutrient media LB, II and NZCYM results in
the synthesis of the target product with the molecular
weight of 34 kDa. The accumulation of the target
protein is 0.152 g out of 1 l of the culture of bacterial
cells using the LB medium, and 0.4 g – using II
medium. The target protein synthesis by the produ-
cent cells cultivated in the NZCYM medium was not
detected by gel-electrophoresis in 13 % polyacrylamide
gel under denaturing conditions with Coumassie stain-
ing, but it was detected by Western-blot analysis. The
level of fragment of E2 CSFV production is 19.54 and
35.62 % at cultivation during 12–18 h after the IPTG
introduction into LB and II media , respectively.
Taking this fact into consideration, only II medium was
used in further experiments. It was shown that dec-
reasing the IPTG concentration in the range of 1 to 0.1
mM results in almost 2-fold lower output of the target
product. The analysis of the dynamics of product ac-
cumulation revealed the increased amount of E2 in the
cells after 12–18 h cultivation compared to that 4 h
after the inductor introduction.
Therefore, the maximal level of the E2 CSFV
synthesis (up to 0.4 g/l of the cultivation medium) was
observed while cultivating the culture for] 12-18 h after
the introduction of IPTG (to the final concentration of
1 mM) on II medium. The study on the distribution of
the synthesized fragment of E2 CSFV in E. coli cells
demonstrated that it was accumulated only as inclu-
sion bodies, which were subsequently isolated after the
cells lysis, solubilized in the buffer with a chaotropic
agent, and renatured. The binding of the preparation of
recombinant E2 in vitro with the antibodies of
hyperimmune porcine serum, obtained as previously
described [8] was used as a test, providing for the
assessment of the accuracy of antigen determinant
formation during renaturation of E2 fragment in vitro
with subsequent checking by dot-blotting (Fig.4).
The experiments studying the action of booster
immunization with E2 CSFV on the immune response,
induced by marker DNA-vaccine against CSF, were
conducted in accordance with the following scheme:
the animals were injected intramuscularly with 100 µg
of candidate marker DNA-vaccine with the two-week
interval. The booster immunization was conducted
three weeks after the second immunization , using the
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Fig. 4 The electrophoregram of aliquots, obtained after the renaturation
and purification of E2 CSFV fragment (1, 2 – fractions, isolated after
consecutive chromatographies on Sephadex G-25 and Q Sepharose
XL; 3 – marker of molecular weight of proteins, PageRuler
TM
Unstained Protein Ladder, Fermentas) (A) and the results of
dot-blotting analysis of E2 CSFV fragment (1 – proteins of the soluble
fraction of cell lysate BL21 (DE3); 2 – E2 CSFV fragment) (B)
0
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Fig. 5 The results of ELISA of blood serum of mice after the third
immunization: 1 – control animals, which were administered with
pTR-UFneo
-
; 2, 3 – animals, which were vaccinated three times with
candidate marker DNA-vaccine (2 – seven days after the third
immunization; 3 – a month later); 4, 5 – animals, vaccinated twice
with candidate marker DNA-vaccine, and vaccinated with E2
fragment for the third time (4 – seven days after the third
immunization; 5 – a month later). The data are presented for the sera
in the working solution with dilution of 1:400; p?0.01; *p>0.05.
same dose of DNA-vaccine for one group, and 30 µg of
the recombinant fragment of E2 CSFV – for the se-
cond. The analysis of the data obtained revealed that the
seroconversion index after the second immunization
was 	 54 %, and 100 % after the third one. This index
did not change in a month since the third immunization.
The results of serum analysis testify that the booster
immunization with E2 CSFV after two immunizations
with marker DNA-vaccine leads to a more significant
increase in the titer of antibodies to the target antigen
compared to three immunizations with DNA-vaccine
(Fig.5). It should also be noted that there was no
reliable sharp decline in the titer of antibodies to E2 in
a month since the booster immunization.
Conclusions. The primers, which allow testing the
presence of the transgen of E2 CSFV in the cells of
murine skeletal muscles, were designed. It was
confirmed that pTR-BKneo- in situ transforms the
biceps cells and the fragment of E2 CSFV is expressed
from the introduced plasmid construction. It was
demonstrated that on the 3rd day after the introduction
of the candidate marker DNA-vaccine against CSF the
target antigen is mainly expressed in the myocytes of
skeletal muscle tissue.
The investigations, aimed at the optimization of
conditions of the E2 CSFV in E. coli cells, strain BL21
(DE3), demonstrated that the accumulation of the target
protein is at least 0.4 g from 1 l of the culture of
bacterial cells when using the selected conditions of
cultivation on the medium BactoTMBrain heart
infusion Porcine.
It was revealed that the seroconversion index after
double immunization with candidate marker
DNA-vaccine was 	 54 %, while the booster
immunization with the same DNA-vaccine or
recombinant fragment of E2 CSFV increased this index
to 100 %.
Therefore, it may be assumed that the application of
the booster immunization with recombinant E2
promotes the elicited humoral immune response to the
candidate marker DNA-vaccine against CSF. It is
noteworthy that the booster immunization with the
recombinant protein results in a more considerable
increase in the titer of antibodies to the target antigen
compared to the studied DNA-vaccine.
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Âëèÿíèå áóñòåðíîé èììóíèçàöèè ôðàãìåíòà Å2 ÂÊ×Ñ íà
èììóííûé îòâåò, èíäóöèðîâàííûé ìàðêèðîâàííîé
ÄÍÊ-âàêöèíîé ïðîòèâ Ê×Ñ
Èíñòèòóò ìîëåêóëÿðíîé áèîëîãèè è ãåíåòèêè ÍÀÍ Óêðàèíû
Óë. Àêàäåìèêà Çàáîëîòíîãî, 150, Êèåâ, Óêðàèíà, 03680
1
Èíñòèòóò âåòåðèíàðíîé ìåäèöèíû ÍÀÀÍ Óêðàèíû
Óë. Äîíåöêàÿ, 30, Êèåâ, Óêðàèíà, 03151
Ðåçþìå
Öåëü. Èññëåäîâàòü âëèÿíèå áóñòåðíîé èììóíèçàöèè ðåêîìáè-
íàíòíûì ôðàãìåíòîì Å2 ÂÊ×Ñ íà ãóìîðàëüíûé èììóííûé îò-
âåò, èíäóöèðîâàííûé êàíäèäàòíîé ìàðêèðîâàííîé
ÄÍÊ-âàêöèíîé ïðîòèâ Ê×Ñ. Ìåòîäû. Íàëè÷èå ôðàãìåíòà ãåíà
Å2 ÂÊ×Ñ äåòåêòèðîâàëè ìåòîäîì ÏÖÐ, à ýêñïðåññèþ áåëêà –
ïðîäóêòà ýòîãî ãåíà – èììóíîãèñòîõèìè÷åñêèì ìåòîäîì. Òèòð
àíòèòåë, ñïåöèôè÷íûõ ê öåëåâîìó àíòèãåíó, â ñûâîðîòêå êðîâè
ïîñëå èììóíèçàöèè îïðåäåëÿëè ñ èñïîëüçîâàíèåì ÈÔÀ. Ðåçóëüòà-
òû. Ïðîäåìîíñòðèðîâàíî, ÷òî êàíäèäàòíàÿ ìàðêèðîâàííàÿ
ÄÍÊ-âàêöèíà òðàíñôåöèðóåò in situ ìèîöèòû áèöåïñà. Íà îñíîâå
äàííûõ èììóíîãèñòîõèìè÷åñêîãî àíàëèçà óñòàíîâëåíî, ÷òî ñ
ââåäåííîé ïëàçìèäíîé êîíñò- ðóêöèè îñóùåñòâëÿåòñÿ ýêñïðåññèÿ
ôðàãìåíòà Å2 ÂÊ×Ñ. Áóñòåðíàÿ èììóíèçàöèÿ ðåêîìáèíàíòíûì
ôðàãìåíòîì Å2 ÂÊ×Ñ ïîñëå äâóõ èììóíèçàöèé ìàðêèðîâàííîé
ÄÍÊ-âàêöèíîé ïðèâîäèò ê óâåëè÷åíèþ òèòðà àíòèòåë ê öåëåâî-
ìó àíòèãåíó ïî ñðàâíåíèþ ñ òðåõêðàòíîé èììóíèçàöèåé
ÄÍÊ-âàêöèíîé. Âûâîäû. Ðåçóëüòàòû ïðîâåäåííûõ èññëåäîâàíèé
ñâèäåòåëüñòâóþò î òîì, ÷òî èñïîëüçîâàíèå áóñòåðíîé èììóíè-
çàöèè ðåêîìáèíàíòíûì ôðàãìåíòîì Å2 ñïîñîáñòâóåò óñèëåíèþ
ãóìîðàëüíîãî èììóííîãî îòâåòà íà êàíäèäàòíóþ ìàðêèðîâàí-
íóþ ÄÍÊ-âàêöèíó ïðîòèâ Ê×Ñ.
Êëþ÷åâûå ñëîâà: ìàðêèðîâàííàÿ ÄÍÊ-âàêöèíà, áóñòåðíàÿ
èììóíèçàöèÿ, ãóìîðàëüíûé èììóííûé îòâåò, âèðóñ êëàññè÷åñ-
êîé ÷óìû ñâèíåé.
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Âïëèâ áóñòåðíî¿ ³ìóí³çàö³¿ ôðàãìåíòîì Å2 ÂÊ×Ñ
íà ³ìóííó â³äïîâ³äü, ³íäóêîâàíó ìàðêîâàíîþ
ÄÍÊ-âàêöèíîþ ïðîòè Ê×Ñ
Ðåçþìå
Ìåòà. Äîñë³äèòè âïëèâ áóñòåðíî¿ ³ìóí³çàö³¿ ðåêîìá³íàíòíèì
ôðàãìåòîì Å2 ÂÊ×Ñ íà ãóìîðàëüíó ³ìóííó â³äïîâ³äü, ³íäóêîâàíó
êàíäèäàòíîþ ìàðêîâàíîþ ÄÍÊ-âàêöèíîþ ïðîòè Ê×Ñ. Ìåòîäè.
Íàÿâí³ñòü ôðàãìåíòà ãåíà Å2 ÂÊ×Ñ äåòåêòóâàëè ìåòîäîì ÏËÐ,
à åêñïðåñ³þ á³ëêà – ïðîäóêòó öüîãî ãåíà – ³ìóíîã³ñòîõ³ì³÷íèì ìå-
òîäîì. Òèòð àíòèò³ë, ñïåöèô³÷íèõ äî ö³ëüîâîãî àíòèãåíó, ó ñè-
ðîâàòö³ êðîâ³ ï³ñëÿ ³ìóí³çàö³¿ âèçíà÷àëè, âèêîðèñòîâóþ÷è ²ÔÀ.
Ðåçóëüòàòè. Ïðîäåìîíñòðîâàíî, ùî êàíäèäàòíà ìàðêîâàíà ÄÍÊ-
âàêöèíà in situ òðàíñô³êóº ì³îöèòè á³öåïñà. Íà îñíîâ³ äàíèõ ³ìó-
íîã³ñòîõ³ì³÷íîãî àíàë³çó âñòàíîâëåíî, ùî ç ââåäåíî¿ ïëàçì³äíî¿
êîíñòðóêö³¿ çä³éñíþºòüñÿ åêñïðåñ³ÿ ôðàãìåíòà Å2 ÂÊ×Ñ. Áóñ-
òåðíà ³ìóí³çàö³ÿ ðåêîìá³íàíòíèì Å2 ÂÊ×Ñ ï³ñëÿ äâîõ ³ìóí³çàö³é
ìàðêîâàíîþ ÄÍÊ-âàêöèíîþ ñïðè÷èíÿº çðîñòàííÿ òèòðó àíòè-
ò³ë äî ö³ëüîâîãî àíòèãåíó ó ïîð³âíÿíí³ ç òðèðàçîâîþ ³ìóí³çàö³ºþ
ÄÍÊ-âàêöèíîþ. Âèñíîâêè. Ðåçóëüòàòè ïðîâåäåíèõ äîñë³äæåíü
ñâ³ä÷àòü ïðî òå, ùî âèêîðèñòàííÿ áóñòåðíî¿ ³ìóí³çàö³¿ ðåêîìá³-
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íàíòíèì ôðàãìåíòîì Å2 ñïðèÿº ïîñèëåííþ ãóìîðàëüíî¿ ³ìóííî¿
â³äïîâ³ä³ íà êàíäèäàòíó ìàðêîâàíó ÄÍÊ-âàêöèíó ïðîòè Ê×Ñ.
Êëþ÷îâ³ ñëîâà: ìàðêîâàíà ÄÍÊ-âàêöèíà, áóñòåðíà ³ìóí³çà-
ö³ÿ, ãóìîðàëüíà ³ìóííà â³äïîâ³äü, â³ðóñ êëàñè÷íî¿ ÷óìè ñâèíåé.
REFERENCES
1. Beer M., Reinmann I., Hoffman B., Depner K. Novel marker
vaccines against classical swine fever // Vaccine.–2007.–25,
N 30.–P. 5665–5670.
2. Vasilyev D. À., Lugovtcev V. Iu. The course of lectures in viro-
logy // Viruses causing diseases of swine.–Ulyanovsk: USAA,
2004.–Part 3.–85 p.
3. Tarradas J., Alvarez B., Fraile L., Rosell R., Munoz M., Galin-
do-Cardiel I., Domingo M., Dominguez J., Ezquerra A., Sobrino
F., Ganges L. Immunomodulatory effect of swine CCL20 che-
mokine in DNA vaccination against CSFV // Vet. Immunol. Im-
munopathol.–2011.–142, N 3–4.–P. 243–251.
4. Wienhold D., Armengol E., Maroquardt A., Maroquardt C., Voigt
H., Buttner M., Saalmuller A., Pfaff E. Immunomodulatory ef-
fect of plasmids co-expressing cytokines in classical swine fever
virus subunit gp55/E2-DNA vaccination // Vet. Res.–2005.–36,
N 4.–P. 571–587.
5. Ganges L., Barrera M., Nunez J. I., Blanco I., Frias M. T., Rod-
riges F., Sobrino F. A DNA vaccine expressing the E2 protein of
classical swine fever virus elicits T cell responses that can prime
for rapid antibody production and confer total protection upon
viral challenge // Vaccine.–2005.–23, N 28.–P. 3741–3752.
6. Makowska-Daniel I., Collins R. A., Pejsak Z. Evaluation of gene-
tic vaccine against classical swine fever // Vaccine.–2001.–19,
N 17–19.–P. 2480–2484.
7. Yu X., Tu C., Li H., Hu R., Chen C., Li Z., Zhang M., Yin Z. DNA-
mediated protection against classical swine fever virus // Vacci-
ne.–2001.–19, N 11–12.–P. 1520–1525.
8. Pokholenko I. A., Ruban T. O., Sukhorada O. M., Deriabin O. M.,
Tytok T. G., Kordium V. A. The development of DNA-vaccine
against classical swine fever // Biopolym. Cell.–2007.–23, N 2.–
P. 93–99.
9. Schneeweiss A., Chabiersli S., Salomo M., Delaroque N., Al-Ro-
baiy S., Grunwald T., Burki K., Liebert U. G., Ulbert S. A DNA
vaccine encoding the E protein of West Nile virus is protective
and can be boosted by recombinant domain DIII // Vaccine.–
2011.–29, N 37.–P. 6352–6357.
10. Zhao H. P., Sun J. F., Li N., Sun Y., Wang Y., Qui H. J. Prime-
boost immunization using alphavirus replicon and adenovirus
vectored vaccines induces enhanced immune responses against
classical swine fever virus in mice // Vet. Immunol. Immunopa-
thol.–2009.–131, N 3–4.–P. 158–166.
11. Hammond J. M., Jansen E. S., Morrissy C. J., Goff W. V., Mee-
han G. C., Williamson M. M., Lenghaus C., Sproat K. W., Andrew
M. E., Coupar B. E., Johnson M. A. A prime-boost vaccination
strategy using naked DNA followed by recombinant porcine ade-
novirus protects pigs from classical swine fever // Vet. Micro-
biol.–2001.–80, N 2.–P. 101–119.
12. Sambrook J., Fritsch E. E., Maniatis T. Molecular cloning.–
Cold Spring Harbor Lab. press, 1989.–625 p.
13. Yamamoto T., Horikoshi M. Rapid preparation of plasmid temp-
lates suitable for a DNA sequences without RNAse treatment //
Nucleic Acids Res.–1995.–23, N 16.–P. 3351–3352.
14. Current protocols in molecular biology / Eds F. M. Ausubel et
al.–New York: John Wiley & Sons, Inc., 1997.–Vol. 1.–
P. 1.7.9–1.7.10.
15. DNA vaccines: methods and protocols / Eds D. B. Lawrie, R. G.
Whalen.–New York: Humana press, 2000.–529 p.
16. Deryabin O., Kulinich R., Deryabina O., Reznik V. Protective
properties of the Classical Swine fever virus E2 recombinant
protein expressed in E. coli // Herald of Bila Tserkva National
Agrarian University.–2005.–31.–P. 151–158.
17. Dupuis M., Denis-Mize K., Woo C., Goldbeck C., Selby M. J.,
Chen M., Otten G. R., Ulmer J. B., Donnelly J. J., Ott G., McDo-
nald D. M. Distribution of DNA vaccines determines their im-
munogenicity after intramuscular injection in mice // J. Immu-
nol.–2000.–165, N 5.–P. 2850–2858.
Received 26.07.11
